Abstract 977P
Background
Hepatocellular carcinoma (HCC) is a prevalent malignant tumor globally, Hence, there is an urgent need for safer and more effective options to improve the survival rates of HCC patients. This study aims to evaluate the viability, efficacy, and safety of HAIC and Regorafenib combined with PD-1 inhibitors for treating advanced HCC patients.
Methods
This is a multicenter, randomized controlled clinical study of hepatocellular carcinoma. Eligible individuals with unresectable HCC were randomized into either the HAIC combined with regorafenib and PD-1 inhibitors group (HAIC+REG+ICIs group) or the regorafenib combined with PD-1 inhibitors group (REG+ICIs group). The primary endpoint is the objective response rate (ORR). Secondary endpoints include PFS, OS, DCR (all assessed by BICR per RECIST v1.1), and safety.
Results
Up to April 24, 2023, a total of 45 patients were enrolled and all patients are available for analysis. The HAIC+REG+ICIs group and the REG+ICIs group included 28 and 17 patients, respectively.The median age were 52.5 years (range, 32-68) and 47.0 years (range, 24-79), 92.9% and 94.1% were male for each group, the proportions of child-pugh A/B were 64.3%/35.7% vs. 88.2%/11.8%; and the patients with China Liver Cancer Staging (CNLC) Ib/IIa/IIb/IIIa/IIIb/IV stage were 0.0%/3.6%/35.7%/21.4%/32.1%/7.1% vs. 5.9%/11.8%/47.1%/11.8%/17.6%/5.9%, respectively. All patients were infected with HBV. The median follow-up time was 16.6 months (1-21.2). The ORR was 39.3% (11/28) and 29.4%(5/17) for HAIC+REG+ICIs group and the REG+ICIs group, P=0.502. DCR was 82.1%(23/28) and 52.9%(9/17) respectively, P=0.036. The median OS of HAIC+REG+ICIs group was significant longer than REG+ICIs group (19.1 vs. NA months, P=0.03; HR=0.039 95% CI: 0.101-0.941). This study is currently ongoing.
Conclusions
HAIC combined with Regorafenib and PD-1 inhibitors compared with Regorafenib and PD-1 inhibitors showed a better tumor response rate, but there was no significant difference. However HAIC combined with regorafenib and PD-1 inhibitors can significantly prolong the overall survival of second-line HCC patients.
Clinical trial identification
ChiCTR2100046555.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18